scholarly journals Interleukin 6 as a predictive biomarker for atrial fibrillation after coronary bypass grafting: a systematic review

2021 ◽  
Vol 8 ◽  
Author(s):  
Roberta Gomes da Mata ◽  
Ana Luisa Adorno de Lima ◽  
Antonio Da Silva Menezes Junior
Keyword(s):  
Atrial Fibrillation ◽  
Systematic Review ◽  
Interleukin 6 ◽  
Plasma Levels ◽  
Artery Bypass ◽  
Coronary Bypass ◽  
Cochrane Library ◽  
Bypass Grafting ◽  
Coronary Bypass Grafting ◽  
Mesh Terms

Atrial fibrillation (AF) progresses after coronary bypass grafting in 11–40% of patients. Plasma biomarkers such as interleukin 6 (IL-6) can assess the risk of AF development. We performed a systematic review using as sources:  PubMed, LILACS, and Cochrane Library databases were investigated using Boolean operators and MeSH terms (Medical Subject Headings Terms) “Atrial Fibrillation AND Interleukin AND Biomarkers”.  As the following eligibility criteria: observational studies, studies with coronary artery bypass grafting with plasma levels of IL-6 recorded after screening, 11 articles were selected. Three studies met the inclusion and exclusion criteria. Results: IL-6 levels on AF group - Ishida et al. reported the plasma levels of IL-6 during the post-operative period as 360 ± 143 pg/mL, while Pretorius et al. reported it to be 380.6 ± 151.1 pg/mL. Lastly, Ziabakhsh-Tabari et al. reported a post-operative plasma IL-6 level of 38.2 ± 32 pg/mL. It is considered that new studies about the object are necessary, and these studies should be more standardized. Preferably, it would be important for the daily measurement of IL-6 and its correlation with AF development for statistical analysis to set the best time for sample collection and cut-off value.

Percutaneous coronary intervention for unprotected and protected left main stem disease

2010 ◽  
pp. 313-332
Author(s):  
Christine Hughes ◽  
Bruno Farah ◽  
Jean Fajadet
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Coronary Artery ◽  
Left Main Coronary Artery ◽  
Artery Bypass ◽  
Coronary Bypass ◽  
Coronary Intervention ◽  
Bypass Grafting ◽  
Left Main ◽  
Coronary Bypass Grafting ◽  
Percutaneous Coronary

Significant unprotected left main coronary artery (ULMCA) disease occurs in 5–7% of patients undergoing coronary angiography (and patients with ULMCA disease treated medically have a 3-year mortality rate of 50%. Several studies have shown a significant benefit following treatment of left main (LM) stenosis with coronary bypass grafting compared with medical treatment. Until recently coronary bypass grafting has been the gold standard therapy for LM disease. However, advances in percutaneous intervention techniques and stent technology have allowed re-evaluation of the role of percutaneous coronary intervention (PCI) for LM disease. Recent studies have focused on the safety and efficacy of stenting the left main coronary artery (LMCA) to determine if it does provide a true alternative to coronary artery bypass grafting (CABG). So should we stent the LM?

scholarly journals Subclinical Hypothyroidism in Coronary Bypass Surgery: Clinically Significant? Or Subclinical after all?

2021 ◽  
Author(s):  
michelle mulder ◽  
Mohammed Jeraq
Keyword(s):  
Atrial Fibrillation ◽  
Subclinical Hypothyroidism ◽  
Bypass Surgery ◽  
Coronary Bypass ◽  
Bypass Grafting ◽  
Coronary Bypass Grafting ◽  
Controversial Topic ◽  
Comprehensive Manner ◽  
Clinically Significant ◽  
Cabg Patients

In this issue, Zhao et al. investigate the effects of subclinical hypothyroidism in coronary bypass grafting particularly with respect to the incidence of atrial fibrillation. While not the first of its kind, the authors analyze this controversial topic in a well powered, statistically comprehensive manner that furthers our understanding of the effects of SCH in CABG patients.

Sign in / Sign up

Export Citation Format

Share Document